Using Monoclonal Antibody Treatments for COVID-19 Positive Patients

To prevent hospitalizations and deaths, monoclonal antibodies have recently been approved by the FDA under Emergency Use Authorization for those who develop or are exposed to COVID-19, have mild or moderate symptoms and are at high risk of developing severe illness. What does this mean for your patients? Get the answers you need from expert Steven Atkinson, PA-C, MS, as he examines early results of this treatment and its level of effectiveness. Enjoyed this presentation? Then we hope you’ll join us for an expert-packed Geriatric Summit on October 26-28. Leaders in the field like Steven Atkinson, PA-C, MS, and 15 multidisciplinary experts will share their expertise on dementia, fall prevention, transitions of care and more! https://bit.ly/3FJUUkx